SEIKAGAKU CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 737 JPY | +0.27% |
|
-0.41% | -3.15% |
| Sales 2024 * | 36.1B 228M 18.25B | Sales 2025 * | 34.5B 218M 17.44B | Capitalization | 40.21B 254M 20.33B |
|---|---|---|---|---|---|
| Net income 2024 * | 2.6B 16.41M 1.31B | Net income 2025 * | 1.76B 11.11M 890M | EV / Sales 2024 * | 0.43 x |
| Net cash position 2024 * | 24.85B 157M 12.56B | Net cash position 2025 * | 26.17B 165M 13.23B | EV / Sales 2025 * | 0.41 x |
| P/E ratio 2024 * |
15.5
x | P/E ratio 2025 * |
22.8
x | Employees | 976 |
| Yield 2024 * |
3.53% | Yield 2025 * |
3.53% | Free-Float | 61.88% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +0.27% | ||
| 1 week | -0.41% | ||
| Current month | -3.66% | ||
| 1 month | -5.03% | ||
| 3 months | -4.53% | ||
| 6 months | -7.18% | ||
| Current year | -3.15% |
1 week
733.00
749.00
1 month
733.00768.00
Current year
733.00788.00
1 year
726.00857.00
3 years
726.001 201.00
5 years
726.001 341.00
10 years
726.002 396.00
| Managers | Title | Age | Since |
|---|---|---|---|
Ken Mizutani
PSD | President | 76 | 31/07/88 |
Takayuki Akita
ADM | Chief Administrative Officer | 60 | 31/05/17 |
Yosuke Funakoshi
CTO | Chief Tech/Sci/R&D Officer | 58 | 31/07/14 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ken Mizutani
PSD | President | 76 | 31/07/88 |
Eiji Katayama
BRD | Director/Board Member | 73 | 31/05/97 |
Toshiyuki Okada
BRD | Director/Board Member | 63 | 31/08/15 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.09% | 15 M€ | +7.34% | ||
| 0.01% | 18 M€ | +16.15% | - | |
| 0.01% | 144,586 M€ | +14.49% | ||
| 0.01% | 66,066 M€ | +14.68% | - | |
| 0.01% | 20,721 M€ | +13.52% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 737 | +0.27% | 183,500 |
| 25/04/24 | 735 | -1.47% | 149,800 |
| 24/04/24 | 746 | 0.00% | 51,100 |
| 23/04/24 | 746 | +0.13% | 35,600 |
| 22/04/24 | 745 | +0.68% | 53,300 |
Delayed Quote Japan Exchange, April 26, 2024 at 07:00 am
More quotes
SEIKAGAKU CORPORATION is principally engaged in the research, development, purchase, manufacture and sale of pharmaceutical products and limulus amebocyte lysate (LAL). The Company operates in two business segments. The Pharmaceutical business segment provides hyaluronan-based medicines for joint function improvement, ophthalmic operation boosters and submucosal injection materials for endoscopes, as well as drug substances for various pharmaceuticals. The LAL business segment provides reagents for measuring endotoxin.
Sector
Pharmaceuticals
Calendar
12/05/2024
- Q4 2023 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
737
JPY
Average target price
800
JPY
Spread / Average Target
+8.55%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -3.15% | 255M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- 4548 Stock
